Home › Research › Mild cognitive impairment
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
Caroli A, Frisoni GB, Frisoni GB, Alzheimer's Disease Neuroimaging Initiative.. Neurobiology of aging, 2010-06-11
Topic: Amyloid, tau and blood-test diagnosis
The aim of this study was to investigate the dynamics of four of the most validated biomarkers for Alzheimer's disease (AD), cerebro-spinal fluid (CSF) Abeta 1-42, tau, hippocampal volume, and FDG-PET, in patients at different stage of AD. Two hundred twenty-nine cognitively healthy subjects, 154 mild cognitive impairment (MCI) patients converted to AD, and 193 (95 early and 98 late) AD patients were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. For each biomarker, individual values were Z-transformed and plotted against ADAS-cog scores, and sigmoid and linear fits were compared. For most biomarkers the sigmoid model fitted data significantly better than the linear model. Abeta 1-42 time course followed a steep curve, stabilizing early in the disease course. CSF tau and hippocampal volume changed later showing similar monotonous trends, reflecting disease progression. Hippocampal loss trend was steeper and occurred earlier in time in APOE epsilon4 carriers than in non-carriers. FDG-PET started changing early in time and likely followed a linear decline. In conclusion, this study provides the first evidence in favor of the dynamic biomarker model which has recently been proposed.
Key findings
- For most biomarkers the sigmoid model fitted data significantly better than the linear model.
- In conclusion, this study provides the first evidence in favor of the dynamic biomarker model which has recently been proposed.
Why it matters
This study found that Alzheimer's disease biomarkers such as cerebrospinal fluid Abeta 1-42, tau, hippocampal volume, and FDG-PET follow different patterns of change over the course of the disease. The findings describe how biomarkers change over time and do not report on treating, curing, or preventing Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurobiology of aging) |
| Journal's citation record | 3 / 4 | Neurobiology of Aging: journal h-index 263 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 149 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 4 / 6 | Cited 10.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 14 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Giovanni Battista Frisoni: h-index 120 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Mario Negri Institute for Pharmacological Research: institution h-index 755 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20538373) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neurobiolaging.2010.04.024
- PubMed: 20538373
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Caroli, A., Frisoni, G. B., & Alzheimer's Disease Neuroimaging Initiative. (2010). The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiology of aging. https://doi.org/10.1016/j.neurobiolaging.2010.04.024
Vancouver
Caroli A, Frisoni GB, Alzheimer's Disease Neuroimaging Initiative. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiology of aging. 2010. doi:10.1016/j.neurobiolaging.2010.04.024. PMID: 20538373.
BibTeX
@article{caroli2010-20538373,
author = {Caroli, A. and Frisoni, G. B. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort}},
journal = {Neurobiology of aging},
year = {2010},
doi = {10.1016/j.neurobiolaging.2010.04.024},
pmid = {20538373},
url = {https://doi.org/10.1016/j.neurobiolaging.2010.04.024}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 34.
Later studies that cite this one
14 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.